{
  "figure_1": "Longitudinal registration count (A) and landscape (B) of immuno‐oncology (IO) trials from different geographic origins and the distribution in 17 cancer types (C). No relevant data were reported in 2005, so this node is omitted on the abscissa [Color figure can be viewed at wileyonlinelibrary.com]",
  "figure_2": "Overview of trial designs (A) and ICI targets (B). CT, conventional therapies; CTLA‐4, cytotoxic T lymphocyte‐associated antigen‐4; ICI, immune checkpoint inhibitor; IO, immuno‐oncology; NR, not reported; PD‐1, programmed cell death‐1; PD‐L1, the ligand of programmed cell death‐1 [Color figure can be viewed at wileyonlinelibrary.com]",
  "figure_3": "Landscape of the composition and proportion of sponsorship according to immuno‐oncology (IO) category and trial phase. The dotted line represents the average sponsorship ratio of all sponsors to IO trials [Color figure can be viewed at wileyonlinelibrary.com]",
  "figure_4": "Intensity of restrictions on corticosteroid‐ and infection‐related criteria (A,B) and the trend in attitudes toward corticosteroid administration in IO trials (C). HIV, human immunodeficiency virus; IO, immuno‐oncology [Color figure can be viewed at wileyonlinelibrary.com]",
  "figure_5": "Publication outlines (A‐C) and cumulative dissemination rates of trial results via journal article (D‐G) and ClinicalTrials.gov registry (H‐K) according to immuno‐oncology (IO) category, geographic origin, sponsor and the attitude to corticosteroid administration. Only the comparisons and P‐values indicating significant differences between publication curves were displayed. The wide dotted line (D‐G) represents the time point we proposed as the timely publication for IO trials. The narrow dotted line (H‐K) indicates the legal requirement of 1 year to report trial results on ClinicalTrials.gov [Color figure can be viewed at wileyonlinelibrary.com]"
}